证券代码：832982 证券简称：锦波生物 公告编号：2024-041 山西锦波生物医药股份有限公司 2023 年年度权益分派实施公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 山西锦波生物医药股份有限公司 2023 年年度权益分派方案已获 2024 年 4 月 16 日召开的股东大会审议通过，本次实施分配方案距离股东大会审议通过的 时间未超过两个月。 现将权益分派事宜公告如下： 本次权益分派基准日合并报表归属于母公司的未分配利润为 520,712,396.75 元，母公司未分配利润为 585,697,862.03 元，母公司资本公积为 334,005,348.74 元（其中股票发行溢价形成的资本公积为 334,005,348.74 元，其他资本公积为 0 元）。本次权益分派共计转增 20,425,800 股，派发现金红利 68,086,000.00 元。 一、权益分派方案 1、本公司 2023 年年度权益分派方案为： 以公司现有总股本 68,086,000 股为基数，向全体股东每 10 股转增 ...

证券代码：832982 证券简称：锦波生物 公告编号：2024-043 山西锦波生物医药股份有限公司 第三届监事会第二十四次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 本次会议的召集、召开、审议过程符合《中华人民共和国公司法》等有关 法律、行政法规、部门规章、规范性文件及《公司章程》的规定。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 监事汤莉因外地出差以通讯方式参与表决。 二、议案审议情况 根据《公司法》《公司章程》等的规定，公司已编制完成《2024 年第一季 1.会议召开时间：2024 年 4 月 19 日 2.会议召开地点：公司四楼会议室 3.会议召开方式：现场加通讯 4.发出监事会会议通知的时间和方式：2024 年 4 月 14 日以电话方式通知 5.会议主持人：监事会主席汤莉女士 6.召开情况合法、合规、合章程性说明： 度报告》。具体内容请详见公司于 2024 年 4 月 22 日在北京证券交易所信息披 ...

证券代码：832982 证券简称：锦波生物 公告编号：2024-042 山西锦波生物医药股份有限公司 第三届董事会第二十九次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 4 月 19 日 2.会议召开地点：公司四楼会议室 3.会议召开方式：现场加通讯 4.发出董事会会议通知的时间和方式：2024 年 4 月 17 日以邮件方式发出 5.会议主持人：董事长杨霞女士 6.会议列席人员：薛芳琴、兰小宾、汤莉、于玉凤 7.召开情况合法、合规、合章程性说明： 本次会议的召集、召开、审议过程符合《中华人民共和国公司法》等有关 法律、行政法规、部门规章、规范性文件及《公司章程》的规定。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 董事金雪坤、李万程因外地出差以通讯方式参与表决。 董事李凡、梁桐栋、阎丽明、张金鑫因外地办公以通讯方式参与表决。 二、议案审议情况 （一）审议通过《关于公司 2024 年 ...

Investment Rating - The report maintains a "Buy" rating for the company, with a target price expected to yield over 20% relative return within the next six months [7][20]. Core Views - The company is expected to achieve a net profit attributable to shareholders of between 0.85 billion and 1.05 billion yuan for Q1 2024, representing a year-on-year increase of 97.65% to 144.16% [5][6]. - The company is focusing on enhancing its brand presence and market expansion through strategic partnerships, such as its collaboration with Shiseido to strengthen its high-end market positioning [5][6]. - The report highlights the company's robust product pipeline and ongoing marketing efforts, which are anticipated to drive sustained revenue growth [6][8]. Financial Performance Summary - The company's revenue is projected to grow from 390.20 million yuan in 2022 to 2,378.26 million yuan by 2026, reflecting a compound annual growth rate (CAGR) of approximately 67.15% to 35.00% over the forecast period [8][10]. - The net profit attributable to shareholders is expected to increase from 109.18 million yuan in 2022 to 894.13 million yuan in 2026, with significant growth rates of 90.24% in 2022 and 31.10% in 2026 [8][10]. - The company's EBITDA is forecasted to rise from 200.41 million yuan in 2022 to 1,094.96 million yuan in 2026, indicating strong operational efficiency and profitability [8][10]. Market Position and Strategy - The company is positioned as a leader in the collagen market, with strategic collaborations enhancing its competitive edge and market share [6][8]. - The report emphasizes the importance of the company's ongoing research and development efforts, which are expected to yield innovative products and maintain its market leadership [6][8]. - The partnership with major brands like L'Oréal is expected to further solidify the company's supply chain and product quality, driving demand in the high-end segment [6][8].

证券代码：832982 证券简称：锦波生物 公告编号：2024-039 山西锦波生物医药股份有限公司 2023 年年度股东大会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 1.会议召开时间：2024 年 4 月 16 日 2.会议召开地点：山西综改示范区太原唐槐园区锦波街 18 号公司九楼会议 室 3.会议召开方式：现场投票加网络投票 4.会议召集人：公司董事会 5.会议主持人：公司董事长杨霞女士 6.召开情况合法、合规、合章程性说明： 2024 年 3 月 19 日，公司第三届董事会第二十八次会议审议通过了《关于 提请召开 2023 年年度股东大会的议案》。 本次股东大会的召集、召开程序符合有关法律、行政法规、部门规章、规 范性文件和本公司章程的相关规定。本次会议召开不需要相关部门的批准或履 行其他必要的程序。 （二）会议出席情况 （一）会议召开情况 出席和授权出席本次股东大会的股东共 25 人，持有表决权的股份总数 45,715,601 股，占公司有表决权股份总数 ...

G E U A N Y 格 远 律 师 事 务 所 aw Firm 关于山西锦波生物医药股份有限公司 2023 年年度股东大会的 法律意见书 山西格 元律师事 山西格远律师事务所 关于山西锦波生物医药股份有限公司 2023 年年度股东大会的 法律意见书 致:山西锦波生物医药股份有限公司 根据《中华人民共和国证券法》(2019年修订(以下简称"《证券法》") 《中华人民共和国公司法(2018年修正)》（以下简称"《公司法》")《北 京证券交易所上市公司持续监管办法》《上市公司信息披露管理办法》等法律、 法规和其他有关规范性文件的要求,山西格远律师事务所(以下简称"本所") 接受山西锦波生物医药股份有限公司(以下简称"锦波生物"或"公司")的委 托,指派律师参加公司 2023 年年度股东大会(以下简称"本次股东大会"或"本 次会议"）。 为出具本《法律意见书》,本所声明如下: 1、本所律师仅对本次股东大会的召集程序、召开程序、出席会议人员资格、 召集人资格、表决程序、表决结果及会议决议发表法律意见,并不对本次股东大 会所审议的议案、议案所涉及的数字及内容发表意见。 2、本所及经办律师依据《证券法》《律师事务所从事 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [10] Core Views - The company is expected to achieve significant growth in its medical beauty business, driven by a strong product pipeline and market expansion efforts [19] - The first quarter of 2024 is projected to show a substantial increase in net profit, with estimates ranging from 85 million to 105 million yuan, representing a year-on-year growth of 97.65% to 144.16% [10][19] - The company is focusing on enhancing its brand presence and expanding its distribution channels, which is expected to contribute to sustained high growth in revenue and profit [19] Financial Summary - Total revenue is projected to grow from 390 million yuan in 2022 to 2,623 million yuan by 2026, with a compound annual growth rate (CAGR) of approximately 67.2% from 2022 to 2023 and 39.7% from 2025 to 2026 [11][12] - Net profit is expected to increase from 109 million yuan in 2022 to 979 million yuan by 2026, with a CAGR of 90.2% from 2022 to 2023 and 44.5% from 2025 to 2026 [11][12] - The company's gross margin is projected to remain high, increasing from 85.4% in 2022 to 92.3% by 2026 [11][12] Product Pipeline and Market Position - The company is advancing its product pipeline with several products in late-stage clinical trials, including a recombinant collagen product and an antiviral peptide drug, which are expected to enhance the company's value [19] - The company has established a competitive advantage in the market with its unique product offerings and strong brand positioning, particularly in the high-end segment of the medical beauty industry [19] - The collaboration with Shulike is expected to accelerate market penetration and enhance brand recognition among consumers [19]

Financial Performance - The estimated net profit attributable to shareholders for Q1 2024 is projected to be between 85 million to 105 million CNY, representing a year-on-year increase of 97.65% to 144.16% compared to 43 million CNY in the same period last year[3]. - The financial data presented is preliminary and has not been audited, with final figures to be disclosed in the Q1 2024 report[2][9]. Research and Development - The company has increased its R&D investment and is actively developing new products and product upgrades, contributing to sustainable revenue growth[8].

| 日期 | 代码 | 简称 | 成交价 | 成交数量（股） | 买入营业部 | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | | 2024-04- | 832982 | 锦波生物 | | | 国泰君安证券股份有 限公司北京光华路营 | 中国银河证券股份有 限公司太原迎泽桥西 | | 12 | | | 137.97 | 289800 | | | | | | | | | 业部 | 证券营业部 | | 2024-04- 12 | 833575 | 康乐卫士 | 20 | 2950000 | 国盛证券有限责任公 | 中信建投证券股份有 限公司南昌北京东路 | | | | | | | 司南昌世贸路营业部 | | | | | | | | | 证券营业部 | | 2024-04- | 873223 | 荣亿精密 | 4.4 | | 中信证券股份有限公 司上海漕溪北路证券 | 国投证券股份有限公 司上海黄浦区中山东 | | 12 | | | | 118000 | | | | | | | | | 营业部 | 二路证券营业部 | | 2024-04- | 834033 ...

Investment Rating - The report does not provide a clear investment rating for the company [1][21]. Core Insights - The company, Jinbo Biological, reported a significant increase in revenue and net profit for 2023, achieving an operating income of 780 million yuan, a year-on-year growth of 100%, and a net profit attributable to shareholders of 300 million yuan, a year-on-year increase of 175% [13][16]. - The fourth quarter of 2023 saw the company generate revenue of 263 million yuan, reflecting a 90% year-on-year growth, with a net profit of 108 million yuan, up 176% year-on-year [15][16]. - The company has made substantial progress in its single material and raw material business, with high-value-added products driving profitability [14][16]. - The partnership with L'Oréal Group for the sale of restructured collagen raw materials marks a significant milestone for the company, potentially enhancing its scale [16][24]. Summary by Sections Financial Performance - In 2023, the company achieved a gross profit margin of 90%, an increase of 4.7 percentage points year-on-year, primarily due to the significant growth in single material medical devices [24]. - The company’s net profit margin for 2023 was 36.6%, up 10.6 percentage points year-on-year [24]. Future Outlook - The company is expected to maintain strong growth, with projected EPS for 2023-2025 at 7.3, 9.7, and 13.2 yuan respectively, maintaining a "buy" rating [16][17]. - The company has a rich pipeline of research projects, including recombinant collagen products that are in clinical stages, which lays a solid foundation for future growth [25]. Market Position - The company has expanded its sales team to 135 members and increased its penetration to 2,000 institutions, indicating rapid channel expansion [24]. - The report highlights the potential risks associated with brand promotion due to rapid channel expansion, which may affect the company's reputation if products are sold through non-compliant channels [19].